SEED Therapeutics Unveils Groundbreaking Advances in Cancer Research at AACR 2025

Jabez Biosciences, Inc. Announced Phase 1 Clinical Trial of JBZ-001 at AACR 2025

Safety, Tolerability, and Preliminary Efficacy of JBZ-001 in Patients with Advanced Solid Tumors and Non-Hodgkin Lymphoma CRANBERRY TOWNSHIP, Pa., May 9, 2025 (Ecnetnews.com) – Jabez Biosciences, Inc., a pioneering biotechnology company focused on innovative cancer therapies, proudly shared the progress of its Phase 1 clinical trial for JBZ-001 (HOSU-53), a novel dihydroorotate dehydrogenase (DHODH) inhibitor, at the American Association for Ca…

SEED Therapeutics Unveils Groundbreaking Advances in Cancer Research at AACR 2025

KING OF PRUSSIA, PA — SEED Therapeutics Inc. presented compelling developments from its cancer research programs at the 2025 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago. The company’s cutting-edge RITE3™ platform has yielded promising results in addressing challenging cancer targets, with significant advancements in both Ewing sarcoma treatment and KRAS G12D degradation. Highlighting their innovative RBM39 de…

Jabez Biosciences, Inc. Announced Phase 1 Clinical Trial of JBZ-001 at AACR 2025 - European Business & Finance Magazine

Safety, Tolerability, and Preliminary Efficacy of JBZ-001 in Patients with Advanced Solid Tumors and Non-Hodgkin Lymphoma